{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:39:05Z","timestamp":1790217545466,"version":"4.1.0"},"reference-count":225,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:00:00Z","timestamp":1772928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["EDDPMA-May23\/100051"],"award-info":[{"award-number":["EDDPMA-May23\/100051"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","award":["G101103642"],"award-info":[{"award-number":["G101103642"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000266","name":"Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","award":["EP\/W035049\/1"],"award-info":[{"award-number":["EP\/W035049\/1"]}],"id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000266","name":"Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","award":["EP\/S009000\/1"],"award-info":[{"award-number":["EP\/S009000\/1"]}],"id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.addr.2026.115842","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T07:36:50Z","timestamp":1772696210000},"page":"115842","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Protein-based nanocarriers in the management of hard-to-treat solid tumours"],"prefix":"10.1016","volume":"233","author":[{"given":"Alexander S.","family":"Evtushenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz Lozano","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ljiljana","family":"Fruk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2026.115842_bb0005","first-page":"107","article-title":"Blueprint for cancer research: critical gaps and opportunities","volume":"71","author":"Elmore","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.addr.2026.115842_bb0010","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.addr.2026.115842_bb0015","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","article-title":"Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016\u201340 for 195 countries and territories","volume":"392","author":"Foreman","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2026.115842_bb0020","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","article-title":"Pancreatic cancer","volume":"405","author":"Stoop","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2026.115842_bb0025","first-page":"258","article-title":"Update on pancreatic neuroendocrine tumors","volume":"3","author":"McKenna","year":"2014","journal-title":"Gland Surg."},{"key":"10.1016\/j.addr.2026.115842_bb0030","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2026.115842_bb0035","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"Razumilava","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2026.115842_bb0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.addr.2026.115842_bb0045","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","article-title":"Non-small-cell lung cancer","volume":"10","author":"LEL","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.addr.2026.115842_bb0050","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.48","article-title":"Oesophageal cancer","volume":"3","author":"Smyth","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.addr.2026.115842_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2016.00016","article-title":"Genetics and epigenetics of glioblastoma: applications and overall incidence of IDH1 mutation","volume":"6","author":"Liu","year":"2016","journal-title":"Front. Oncol."},{"key":"10.1016\/j.addr.2026.115842_bb0060","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jama.2023.0023","article-title":"Glioblastoma and other primary brain malignancies in adults","volume":"329","author":"Schaff","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2026.115842_bb0065","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11060-015-1797-y","article-title":"MRI findings and pathological features in early-stage glioblastoma","volume":"123","author":"Ideguchi","year":"2015","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.addr.2026.115842_bb0070","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S2468-1253(19)30416-9","article-title":"Early detection of pancreatic cancer","volume":"5","author":"Pereira","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.addr.2026.115842_bb0075","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkad034","article-title":"Opportunities to address gaps in early detection and improve outcomes of liver cancer","volume":"7","author":"McMahon","year":"2023","journal-title":"JNCI Cancer Spectr."},{"key":"10.1016\/j.addr.2026.115842_bb0080","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae \u2014 the first FDA-approved nano-drug: lessons learned","volume":"160","author":"(Chezy)","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115842_bb0085","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.3390\/cancers15082256","article-title":"A recent review on Cancer nanomedicine","volume":"15","author":"Giri","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2026.115842_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13092058","article-title":"Nanomedicine to overcome multidrug resistance mechanisms in colon and pancreatic cancer: recent progress","volume":"13","author":"Ort\u00edz","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2026.115842_bb0095","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adi2046","article-title":"Antibody nanoparticle conjugate\u2013based targeted immunotherapy for non\u2013small cell lung cancer","volume":"10","author":"Saha","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.addr.2026.115842_bb0100","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1038\/s41591-022-02061-1","article-title":"The landscape of mRNA nanomedicine","volume":"28","author":"Huang","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2026.115842_bb0105","doi-asserted-by":"crossref","first-page":"9994","DOI":"10.1021\/acsnano.2c00128","article-title":"Where is Nano today and where is it headed? A review of nanomedicine and the dilemma of nanotoxicology","volume":"16","author":"Domingues","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115842_bb0110","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41392-023-01536-y","article-title":"Nanomedicine in cancer therapy","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.addr.2026.115842_bb0115","first-page":"17","article-title":"Nanoparticles--a new colloidal drug delivery system","volume":"53","author":"Marty","year":"1978","journal-title":"Pharm. Acta Helv."},{"key":"10.1016\/j.addr.2026.115842_bb0120","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil\u2013based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115842_bb0125","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1200\/JCO.2011.39.5848","article-title":"Weekly nab -paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non\u2013small-cell lung Cancer: final results of a phase III trial","volume":"30","author":"Socinski","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115842_bb0130","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic Cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115842_bb0135","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1200\/JCO.21.01728","article-title":"Nab -sirolimus for patients with malignant perivascular epithelioid cell Tumors","volume":"39","author":"Wagner","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115842_bb0140","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1080\/19420862.2016.1204502","article-title":"In-depth structural characterization of Kadcyla\u00ae (ado-trastuzumab emtansine) and its biosimilar candidate","volume":"8","author":"Chen","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2026.115842_bb0145","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0169-409X(03)00110-8","article-title":"Pegaspargase: a review of clinical studies","volume":"55","author":"Graham","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115842_bb0150","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.addr.2026.115842_bb0155","series-title":"All About Albumin: Biochemistry, Genetics, and Medical Applications","author":"TJr","year":"1996"},{"key":"10.1016\/j.addr.2026.115842_bb0160","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jconrel.2008.05.010","article-title":"Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles","volume":"132","author":"Kratz","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115842_bb0165","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.2147\/IJN.S500997","article-title":"Wolf in sheep\u2019s clothing: taming cancer\u2019s resistance with human serum albumin?","volume":"20","author":"Stukan","year":"2025","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2026.115842_bb0170","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/hep.1840080234","article-title":"Serum albumin","volume":"8","author":"Rothschild","year":"1988","journal-title":"Hepatology"},{"key":"10.1016\/j.addr.2026.115842_bb0175","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.it.2006.05.004","article-title":"Perspective \u2013 FcRn transports albumin: relevance to immunology and medicine","volume":"27","author":"Anderson","year":"2006","journal-title":"Trends Immunol."},{"key":"10.1016\/j.addr.2026.115842_bb0180","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0026-895X(25)10691-3","article-title":"The characterization of two specific drug binding sites on human serum albumin","volume":"11","author":"Sudlow","year":"1975","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.addr.2026.115842_bb0185","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1021\/mp400027q","article-title":"Subdomain IB is the third major drug binding region of human serum albumin: toward the three-sites model","volume":"10","author":"Zsila","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115842_bb0190","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1006\/jmbi.2000.4158","article-title":"Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin 1 1Edited by R. Huber","volume":"303","author":"Bhattacharya","year":"2000","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.addr.2026.115842_bb0195","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The Protein Data Bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.addr.2026.115842_bb0200","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/pro.3235","article-title":"UCSF ChimeraX: meeting modern challenges in visualization and analysis","volume":"27","author":"Goddard","year":"2018","journal-title":"Protein Sci."},{"key":"10.1016\/j.addr.2026.115842_bb0205","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/protein\/12.6.439","article-title":"Crystal structure of human serum albumin at 2.5 \u00c5 resolution","volume":"12","author":"Sugio","year":"1999","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.addr.2026.115842_bb0210","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1148\/92.7.1453","article-title":"Radioactive albumin microspheres for studies of the pulmonary circulation","volume":"92","author":"Rhodes","year":"1969","journal-title":"Radiology"},{"key":"10.1016\/j.addr.2026.115842_bb0215","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1056\/NEJM196408202710801","article-title":"Diagnosis of massive pulmonary embolism in Man by radioisotope scanning","volume":"271","author":"Wagner","year":"1964","journal-title":"New England J. Med."},{"key":"10.1016\/j.addr.2026.115842_bb0220","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0378-5173(81)90100-9","article-title":"Solid colloidal drug delivery systems: nanoparticles","volume":"8","author":"Oppenheim","year":"1981","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115842_bb0225","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/jps.2600631044","article-title":"Albumin microspheres as vehicles for achieving specificity in drug delivery","volume":"63","author":"Kramer","year":"1974","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115842_bb0230","series-title":"Protein Stabilized Pharmacologically Active Agents, Methods for the Preparation Thereof and Methods for the Use Thereof","author":"Desai","year":"1999"},{"key":"10.1016\/j.addr.2026.115842_bb0235","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jconrel.2013.05.041","article-title":"Nab-paclitaxel mechanisms of action and delivery","volume":"170","author":"Yardley","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115842_bb0240","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.critrevonc.2014.06.001","article-title":"Nab-paclitaxel: a flattering facelift","volume":"92","author":"Vi\u00fadez","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.addr.2026.115842_bb0245","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S1548-5315(11)70224-8","article-title":"Cremophor EL-containing paclitaxel-induced anaphylaxis: a call to action","volume":"6","author":"Irizarry","year":"2009","journal-title":"Commun. Oncol."},{"key":"10.1016\/j.addr.2026.115842_bb0250","doi-asserted-by":"crossref","first-page":"5164","DOI":"10.7150\/jca.59794","article-title":"Potentially overestimated efficacy of nanoparticle albumin-bound paclitaxel compared with solvent-based paclitaxel in breast Cancer: a systemic review and Meta-analysis","volume":"12","author":"Li","year":"2021","journal-title":"J. Cancer"},{"key":"10.1016\/j.addr.2026.115842_bb0255","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3892\/ol.2024.14642","article-title":"Efficacy and safety of nanoparticle albumin-bound paclitaxel compared with solvent-based paclitaxel in adjuvant therapy for breast cancer: a retrospective study","volume":"28","author":"Lv","year":"2024","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.addr.2026.115842_bb0260","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2147\/CMAR.S127840","article-title":"<em>nab<\/em>-paclitaxel for the treatment of pancreatic cancer","volume":"9","author":"Kim","year":"2017","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.addr.2026.115842_bb0265","doi-asserted-by":"crossref","first-page":"e791","DOI":"10.1016\/S2666-7568(21)00255-5","article-title":"Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial","volume":"2","author":"Kogure","year":"2021","journal-title":"Lancet Healthy Longev."},{"key":"10.1016\/j.addr.2026.115842_bb0270","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/annonc\/mdx688","article-title":"Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer","volume":"29","author":"Overman","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.addr.2026.115842_bb0275","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.2147\/OTT.S168275","article-title":"Efficacy and safety of weekly nab-paclitaxel plus cisplatin with concurrent intensity-modulated radiotherapy in patients with inoperable, locally advanced esophageal cancer: a pilot trial","volume":"11","author":"Wang","year":"2018","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.addr.2026.115842_bb0280","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2024.35.e111","article-title":"Clinical trial protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer","volume":"35","author":"Olawaiye","year":"2024","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.addr.2026.115842_bb0285","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1021\/acsabm.1c00110","article-title":"Reduction-responsive and multidrug deliverable albumin nanoparticles: an antitumor drug to Abraxane against human pancreatic tumor-bearing mice","volume":"4","author":"Hirakawa","year":"2021","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.addr.2026.115842_bb0290","first-page":"708","article-title":"Paclitaxel and curcumin co-bound albumin nanoparticles having antitumor potential to pancreatic cancer","volume":"11","author":"Kim","year":"2016","journal-title":"Asian J Pharm Sci."},{"key":"10.1016\/j.addr.2026.115842_bb0295","doi-asserted-by":"crossref","first-page":"6278","DOI":"10.1039\/C8TB01613E","article-title":"Safety of nanoparticles based on albumin\u2013polymer conjugates as a carrier of nucleotides for pancreatic cancer therapy","volume":"6","author":"Taguchi","year":"2018","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.addr.2026.115842_bb0300","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.colsurfb.2017.01.017","article-title":"Doxorubicin and paclitaxel co-bound lactosylated albumin nanoparticles having targetability to hepatocellular carcinoma","volume":"152","author":"Thao","year":"2017","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.addr.2026.115842_bb0305","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jconrel.2014.11.008","article-title":"Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer","volume":"197","author":"Choi","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115842_bb0310","doi-asserted-by":"crossref","DOI":"10.1002\/mabi.202100404","article-title":"Peptide modified albumin-paclitaxel nanoparticles for improving chemotherapy and preventing metastasis","volume":"22","author":"Fu","year":"2022","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.addr.2026.115842_bb0315","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1208\/s12249-016-0670-4","article-title":"Development of a more efficient albumin-based delivery system for gambogic acid with low toxicity for lung Cancer therapy","volume":"18","author":"Zhang","year":"2017","journal-title":"AAPS PharmSciTech."},{"key":"10.1016\/j.addr.2026.115842_bb0320","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.apsb.2017.09.008","article-title":"Substance P-modified human serum albumin nanoparticles loaded with paclitaxel for targeted therapy of glioma","volume":"8","author":"Ruan","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.addr.2026.115842_bb0325","doi-asserted-by":"crossref","first-page":"5687","DOI":"10.1038\/s41467-020-19225-7","article-title":"Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy","volume":"11","author":"Gregory","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115842_bb0330","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-05-1634","article-title":"Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel","volume":"12","author":"Desai","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2026.115842_bb0335","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/BF01908027","article-title":"Myocardial fatty acid oxidation: evidence for an albumin-receptor-mediated membrane transfer of fatty acids","volume":"79","author":"H\u00fctter","year":"1984","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.addr.2026.115842_bb0340","doi-asserted-by":"crossref","first-page":"G13","DOI":"10.1152\/ajpgi.1983.245.1.G13","article-title":"Hepatic uptake of albumin-bound substances: albumin receptor concept","volume":"245","author":"Ockner","year":"1983","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.addr.2026.115842_bb0345","doi-asserted-by":"crossref","first-page":"6773","DOI":"10.1073\/pnas.85.18.6773","article-title":"Albumin interacts specifically with a 60-kDa microvascular endothelial glycoprotein","volume":"85","author":"Schnitzer","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.addr.2026.115842_bb0350","doi-asserted-by":"crossref","first-page":"H246","DOI":"10.1152\/ajpheart.1992.262.1.H246","article-title":"gp60 is an albumin-binding glycoprotein expressed by continuous endothelium involved in albumin transcytosis","volume":"262","author":"Schnitzer","year":"1992","journal-title":"American J. Physiol-Heart and Circulatory Physiol."},{"key":"10.1016\/j.addr.2026.115842_bb0355","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1083\/jcb.127.5.1217","article-title":"Filipin-sensitive caveolae-mediated transport in endothelium: reduced transcytosis, scavenger endocytosis, and capillary permeability of select macromolecules","volume":"127","author":"Schnitzer","year":"1994","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.addr.2026.115842_bb0360","doi-asserted-by":"crossref","first-page":"48619","DOI":"10.1074\/jbc.C100613200","article-title":"Caveolae-deficient endothelial cells show defects in the uptake and transport of albumin in vivo","volume":"276","author":"Schubert","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2026.115842_bb0365","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1083\/jcb.107.1.231","article-title":"Identification of albumin-binding proteins in capillary endothelial cells","volume":"107","author":"Ghinea","year":"1988","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.addr.2026.115842_bb0370","doi-asserted-by":"crossref","first-page":"24544","DOI":"10.1016\/S0021-9258(18)35799-5","article-title":"Preferential interaction of albumin-binding proteins, gp30 and gp18, with conformationally modified albumins. Presence in many cells and tissues with a possible role in catabolism","volume":"267","author":"Schnitzer","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2026.115842_bb0375","doi-asserted-by":"crossref","first-page":"L187","DOI":"10.1152\/ajplung.00152.2002","article-title":"Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer","volume":"284","author":"John","year":"2003","journal-title":"American J. Physiol-Lung Cellular and Molecular Physiol."},{"key":"10.1016\/j.addr.2026.115842_bb0380","doi-asserted-by":"crossref","first-page":"19736","DOI":"10.1021\/acsami.1c03065","article-title":"Evidence for delivery of Abraxane via a denatured-albumin transport system","volume":"13","author":"Hama","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.addr.2026.115842_bb0385","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1158\/0008-5472.CAN-17-0604","article-title":"Caveolae-mediated endocytosis is critical for albumin cellular uptake and response to albumin-bound chemotherapy","volume":"77","author":"Chatterjee","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2026.115842_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2017.e00369","article-title":"Human serum albumin and oxidative stress in preeclamptic women and the mechanism of albumin for stress reduction","volume":"3","author":"Kinoshita","year":"2017","journal-title":"Heliyon"},{"key":"10.1016\/j.addr.2026.115842_bb0395","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1329636","article-title":"GP60 and SPARC as albumin receptors: key targeted sites for the delivery of antitumor drugs","volume":"15","author":"Ji","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.addr.2026.115842_bb0400","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2220173120","article-title":"Reverse-QTY code design of active human serum albumin self-assembled amphiphilic nanoparticles for effective anti-tumor drug doxorubicin release in mice","volume":"120","author":"Meng","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.addr.2026.115842_bb0405","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1021\/acsnano.6b04268","article-title":"Blood\u2013brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for Antiglioma therapy","volume":"10","author":"Lin","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115842_bb0410","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1073\/pnas.93.1.250","article-title":"Isolation and characterization of a cell surface albumin-binding protein from vascular endothelial cells","volume":"93","author":"Tiruppathi","year":"1996","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.addr.2026.115842_bb0415","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1096\/fasebj.8.2.8119487","article-title":"The biology of SPARC, a protein that modulates cell-matrix interactions","volume":"8","author":"Lane","year":"1994","journal-title":"FASEB J."},{"key":"10.1016\/j.addr.2026.115842_bb0420","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0092-8674(81)90037-4","article-title":"Osteonectin, a bone-specific protein linking mineral to collagen","volume":"26","author":"Termine","year":"1981","journal-title":"Cell"},{"key":"10.1016\/j.addr.2026.115842_bb0425","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1016\/S0021-9258(17)43194-2","article-title":"Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture","volume":"259","author":"Sage","year":"1984","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2026.115842_bb0430","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/j.1460-2075.1986.tb04383.x","article-title":"Evidence from molecular cloning that SPARC, a major product of mouse embryo parietal endoderm, is related to an endothelial cell \u201cculture shock\u201d glycoprotein of Mr 43,000","volume":"5","author":"Mason","year":"1986","journal-title":"EMBO J."},{"key":"10.1016\/j.addr.2026.115842_bb0435","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1432-1033.1986.tb10466.x","article-title":"Purification and tissue distribution of a small protein (BM-40) extracted from a basement membrane tumor","volume":"161","author":"Dziadek","year":"1986","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.addr.2026.115842_bb0440","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0014-5793(87)81040-2","article-title":"Solubilization of protein BM-40 from a basement membrane tumor with chelating agents and evidence for its identity with osteonectin and SPARC","volume":"218","author":"Mann","year":"1987","journal-title":"FEBS Lett."},{"key":"10.1016\/j.addr.2026.115842_bb0445","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/carcin\/bgu072","article-title":"Molecular mechanisms underlying the divergent roles of SPARC in human carcinogenesis","volume":"35","author":"Nagaraju","year":"2014","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.addr.2026.115842_bb0450","first-page":"H1872","article-title":"Antibodies to SPARC inhibit albumin binding to SPARC, gp60, and microvascular endothelium","volume":"263","author":"Schnitzer","year":"1992","journal-title":"Am. J. Phys. Heart Circ. Phys."},{"key":"10.1016\/j.addr.2026.115842_bb0455","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","article-title":"Gemcitabine plus nab -paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial","volume":"29","author":"Von Hoff","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115842_bb0460","doi-asserted-by":"crossref","first-page":"6663","DOI":"10.2147\/OTT.S114492","article-title":"SPARC is a possible predictive marker for albumin-bound paclitaxel in non-small-cell lung cancer","volume":"9","author":"Komiya","year":"2016","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.addr.2026.115842_bb0465","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1593\/tlo.09109","article-title":"SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck Cancer patients","volume":"2","author":"Desai","year":"2009","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.addr.2026.115842_bb0470","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1158\/1078-0432.CCR-14-3222","article-title":"SPARC expression did not predict efficacy of nab -paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic Cancer in an exploratory analysis of the phase III MPACT trial","volume":"21","author":"Hidalgo","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2026.115842_bb0475","doi-asserted-by":"crossref","first-page":"876","DOI":"10.21037\/tcr-20-3045","article-title":"Investigating the relationship between secreted protein acidic and rich in cysteine expression level and therapeutic efficacy of nab-paclitaxel: a meta-analysis","volume":"10","author":"Zhou","year":"2021","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.addr.2026.115842_bb0480","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/gutjnl-2013-305559","article-title":"SPARC independent drug delivery and antitumour effects of nab -paclitaxel in genetically engineered mice","volume":"63","author":"Neesse","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.addr.2026.115842_bb0485","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00682","article-title":"Unraveling the interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics","volume":"5","author":"Sand","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2026.115842_bb0490","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1084\/jem.20021829","article-title":"The major histocompatibility complex\u2013related fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan","volume":"197","author":"Chaudhury","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.addr.2026.115842_bb0495","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2026.115842_bb0500","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jconrel.2020.03.004","article-title":"FcRn overexpression in human cancer drives albumin recycling and cell growth; a mechanistic basis for exploitation in targeted albumin-drug designs","volume":"322","author":"Larsen","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115842_bb0505","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jconrel.2019.01.014","article-title":"KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs","volume":"296","author":"Liu","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115842_bb0510","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.kint.2015.11.007","article-title":"Megalin and cubilin in proximal tubule protein reabsorption: from experimental models to human disease","volume":"89","author":"Nielsen","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2026.115842_bb0515","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1152\/physiol.00022.2012","article-title":"Endocytic receptors in the renal proximal tubule","volume":"27","author":"Christensen","year":"2012","journal-title":"Physiology"},{"key":"10.1016\/j.addr.2026.115842_bb0520","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1681\/ASN.2013010018","article-title":"Albumin is recycled from the primary urine by tubular transcytosis","volume":"24","author":"Tenten","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2026.115842_bb0525","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1177\/002215549704500306","article-title":"Tissue distribution of human gp330\/Megalin, a putative ca 2+ \u2212sensing protein","volume":"45","author":"Lundgren","year":"1997","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.addr.2026.115842_bb0530","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/ndt\/gfs565","article-title":"From bowel to kidneys: the role of cubilin in physiology and disease","volume":"28","author":"Christensen","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.addr.2026.115842_bb0535","first-page":"L740","article-title":"CD36 mediates albumin transcytosis by dermal but not lung microvascular endothelial cells: role in fatty acid delivery","volume":"316","author":"Raheel","year":"2019","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"key":"10.1016\/j.addr.2026.115842_bb0540","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s42003-020-01294-5","article-title":"Transferrin receptor 1 is a cellular receptor for human heme-albumin","volume":"3","author":"Jennifer","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.addr.2026.115842_bb0545","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s11307-021-01689-8","article-title":"RAS-driven macropinocytosis of albumin or dextran reveals mutation-specific target engagement of RAS p.G12C inhibitor ARS-1620 by NIR-fluorescence imaging","volume":"24","author":"Sutton","year":"2022","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.addr.2026.115842_bb0550","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nature12138","article-title":"Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells","volume":"497","author":"Commisso","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115842_bb0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmgm.2020.107601","article-title":"Exploring how structural and dynamic properties of bovine and canine serum albumins differ from human serum albumin","volume":"98","author":"Ketrat","year":"2020","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.addr.2026.115842_bb0560","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0092-1157(73)90055-3","article-title":"Sensitization against calf serum proteins as a possible cause of allergic reactions after vaccination","volume":"1","author":"Bonin","year":"1973","journal-title":"J. Biol. Stand."},{"key":"10.1016\/j.addr.2026.115842_bb0565","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(02)08627-0","article-title":"Life-threatening anaphylaxis after artificial insemination","volume":"359","author":"Matheu","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2026.115842_bb0570","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.cell.2010.04.012","article-title":"Precision mapping of an in vivo N-glycoproteome reveals rigid topological and sequence constraints","volume":"141","author":"Zielinska","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.addr.2026.115842_bb0575","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1186\/s12967-024-05000-5","article-title":"Defining albumin as a glycoprotein with multiple N-linked glycosylation sites","volume":"22","author":"Garapati","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.addr.2026.115842_bb0580","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1021\/acs.analchem.8b01051","article-title":"Site-specific profiling of serum glycoproteins using N-linked glycan and glycosite analysis revealing atypical N -glycosylation sites on albumin and \u03b1-1B-glycoprotein","volume":"90","author":"Sun","year":"2018","journal-title":"Anal. Chem."},{"key":"10.1016\/j.addr.2026.115842_bb0585","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00807","article-title":"From \u201cserum sickness\u201d to \u201cxenosialitis\u201d: past, present, and future significance of the non-human sialic acid Neu5Gc","volume":"10","author":"Dhar","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2026.115842_bb0590","first-page":"41","article-title":"Bovine sera used in the manufacture of biologicals: current concerns and policies of the U.S. Food and Drug Administration regarding the transmissible spongiform encephalopathies","volume":"99","author":"Asher","year":"1999","journal-title":"Dev. Biol. Stand."},{"key":"10.1016\/j.addr.2026.115842_bb0595","article-title":"Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products","volume":"47","author":"The European Commission","year":"2004","journal-title":"Off. J. Eur. Union"},{"key":"10.1016\/j.addr.2026.115842_bb0600","series-title":"WHO Expert Committee on Biological Standardization: Fifty-Sixth Report. Geneva","author":"World Health Organisation","year":"2007"},{"key":"10.1016\/j.addr.2026.115842_bb0605","doi-asserted-by":"crossref","first-page":"77696","DOI":"10.18632\/oncotarget.12773","article-title":"Secreted protein acidic and rich in cysteine (SPARC) induces lipotoxicity in neuroblastoma by regulating transport of albumin complexed with fatty acids","volume":"7","author":"Chlenski","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.addr.2026.115842_bb0610","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jconrel.2011.02.010","article-title":"Casein-based formulations as promising controlled release drug delivery systems","volume":"153","author":"Elzoghby","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115842_bb0615","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1021\/cr050241v","article-title":"Cytochrome c\u00a0: occurrence and functions","volume":"106","author":"Bertini","year":"2006","journal-title":"Chem. Rev."},{"key":"10.1016\/j.addr.2026.115842_bb0620","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-46880-9","article-title":"Ferritin microheterogeneity, subunit composition, functional, and physiological implications","volume":"13","author":"Srivastava","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2026.115842_bb0625","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/10717544.2020.1736208","article-title":"Fibroin nanoparticles: a promising drug delivery system","volume":"27","author":"Pham","year":"2020","journal-title":"Drug Deliv."},{"key":"10.1016\/j.addr.2026.115842_bb0630","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.3390\/pharmaceutics15051499","article-title":"Current trends in Gelatin-based drug delivery systems","volume":"15","author":"Milano","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115842_bb0635","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00253-008-1407-4","article-title":"Glucose oxidase: natural occurrence, function, properties and industrial applications","volume":"78","author":"Wong","year":"2008","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.addr.2026.115842_bb0640","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/j.2040-4603.2012.tb00415.x","article-title":"Oxygen Transport by Hemoglobin","volume":"2","author":"Mairb\u00e4url","year":"2012","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.addr.2026.115842_bb0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.128763","article-title":"Cryo-EM structure of a 16.5-kDa small heat-shock protein from Methanocaldococcus jannaschii","volume":"258","author":"Lee","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.addr.2026.115842_bb0650","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/antib8010024","article-title":"IgG charge: practical and biological implications","volume":"8","author":"Yang","year":"2019","journal-title":"Antibodies"},{"key":"10.1016\/j.addr.2026.115842_bb0655","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/med.10008","article-title":"Transferrin\/transferrin receptor-mediated drug delivery","volume":"22","author":"Li","year":"2002","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.addr.2026.115842_bb0660","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jconrel.2014.06.036","article-title":"Zein in controlled drug delivery and tissue engineering","volume":"189","author":"Paliwal","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115842_bb0665","series-title":"The Proteomics Protocols Handbook","author":"Walker","year":"2005"},{"key":"10.1016\/j.addr.2026.115842_bb0670","doi-asserted-by":"crossref","first-page":"D368","DOI":"10.1093\/nar\/gkad1011","article-title":"AlphaFold protein structure database in 2024: providing structure coverage for over 214 million protein sequences","volume":"52","author":"Varadi","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.addr.2026.115842_bb0675","first-page":"22","article-title":"Gelatin nanoparticles as a new and simple gene delivery system","volume":"7","author":"Zwiorek","year":"2005","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115842_bb0680","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/10717544.2019.1704942","article-title":"Zein nanoparticles as nontoxic delivery system for maytansine in the treatment of non-small cell lung cancer","volume":"27","author":"Yu","year":"2020","journal-title":"Drug Deliv."},{"key":"10.1016\/j.addr.2026.115842_bb0685","doi-asserted-by":"crossref","first-page":"6820","DOI":"10.1039\/C4SM00239C","article-title":"pH-driven encapsulation of curcumin in self-assembled casein nanoparticles for enhanced dispersibility and bioactivity","volume":"10","author":"Pan","year":"2014","journal-title":"Soft Matter"},{"key":"10.1016\/j.addr.2026.115842_bb0690","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.biopha.2015.02.006","article-title":"Resveratrol loaded gelatin nanoparticles synergistically inhibits cell cycle progression and constitutive NF-kappaB activation, and induces apoptosis in non-small cell lung cancer cells","volume":"70","author":"Karthikeyan","year":"2015","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.addr.2026.115842_bb0695","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.xphs.2018.12.014","article-title":"Immunogenicity of protein pharmaceuticals","volume":"108","author":"Dingman","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115842_bb0700","doi-asserted-by":"crossref","first-page":"6486","DOI":"10.1039\/C8CS00187A","article-title":"Silkworm silk-based materials and devices generated using bio-nanotechnology","volume":"47","author":"Huang","year":"2018","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2026.115842_bb0705","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.matpr.2020.12.922","article-title":"A review of gelatin: properties, sources, process, applications, and commercialisation","volume":"42","author":"Alipal","year":"2021","journal-title":"Mater. Today Proc."},{"key":"10.1016\/j.addr.2026.115842_bb0710","doi-asserted-by":"crossref","DOI":"10.1093\/mtomcs\/mfab021","article-title":"Chemistry and biology of ferritin","volume":"13","author":"Plays","year":"2021","journal-title":"Metallomics"},{"key":"10.1016\/j.addr.2026.115842_bb0715","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202303623","article-title":"Tackling esophageal squamous cell carcinoma with ITFn-pt(IV): a novel fusion of PD-L1 blockade, chemotherapy, and T-cell activation","volume":"13","author":"Xin","year":"2024","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.addr.2026.115842_bb0720","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1002\/smll.201600917","article-title":"Enhanced in vivo tumor detection by active tumor cell targeting using multiple tumor receptor-binding peptides presented on genetically engineered human ferritin nanoparticles","volume":"12","author":"Kwon","year":"2016","journal-title":"Small"},{"key":"10.1016\/j.addr.2026.115842_bb0725","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1073\/pnas.0913192107","article-title":"Binding and uptake of H-ferritin are mediated by human transferrin receptor-1","volume":"107","author":"Li","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.addr.2026.115842_bb0730","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106974","article-title":"L-ferritin binding to Scara5: a new Iron traffic pathway potentially implicated in retinopathy","volume":"9","author":"Mendes-Jorge","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2026.115842_bb0735","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s12032-009-9203-2","article-title":"Altered iron metabolism, inflammation, transferrin receptors, and ferritin expression in non-small-cell lung cancer","volume":"27","author":"Kukulj","year":"2010","journal-title":"Med. Oncol."},{"key":"10.1016\/j.addr.2026.115842_bb0740","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182954","article-title":"Transferrin receptor-1 and ferritin heavy and light chains in astrocytic brain tumors: expression and prognostic value","volume":"12","author":"Rosager","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2026.115842_bb0745","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.ejca.2004.01.036","article-title":"Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas","volume":"40","author":"Ryschich","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.addr.2026.115842_bb0750","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s12072-023-10607-9","article-title":"Transferrin receptor 1 promotes hepatocellular carcinoma progression and metastasis by activating the mTOR signaling pathway","volume":"18","author":"Wang","year":"2024","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.addr.2026.115842_bb0755","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.3892\/or.2014.2981","article-title":"Overexpression of transferrin receptor CD71 and its tumorigenic properties in esophageal squamous cell carcinoma","volume":"31","author":"Chan","year":"2014","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.addr.2026.115842_bb0760","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41591-021-01660-8","article-title":"Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial","volume":"28","author":"Houser","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2026.115842_bb0765","doi-asserted-by":"crossref","first-page":"e581","DOI":"10.1016\/S2666-5247(23)00410-X","article-title":"SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army liposome formulation containing monophosphoryl lipid a and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial","volume":"5","author":"Ober Shepherd","year":"2024","journal-title":"Lancet Microbe."},{"key":"10.1016\/j.addr.2026.115842_bb0770","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.addr.2026.115842_bb0775","doi-asserted-by":"crossref","first-page":"16476","DOI":"10.1039\/C9NR03684A","article-title":"Hierarchical assembly of hyaluronan coated albumin nanoparticles for pancreatic cancer chemoimmunotherapy","volume":"11","author":"Hu","year":"2019","journal-title":"Nanoscale"},{"key":"10.1016\/j.addr.2026.115842_bb0780","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.nano.2014.10.004","article-title":"Albumin nanocapsules containing fenretinide: pre-clinical evaluation of cytotoxic activity in experimental models of human non-small cell lung cancer","volume":"11","author":"Pignatta","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.addr.2026.115842_bb0785","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122711","article-title":"Preclinical evaluation of albumin-bound docetaxel nanoparticles as potential anti-cancer products","volume":"635","author":"Su","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115842_bb0790","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1021\/acsabm.5c00098","article-title":"Ferritin fused with MiniSOG for in vitro photodynamic therapy","volume":"8","author":"Naradun","year":"2025","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.addr.2026.115842_bb0795","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.biomaterials.2017.10.029","article-title":"Ultrasensitive MRI detection of spontaneous pancreatic tumors with nanocage-based targeted contrast agent","volume":"152","author":"Kawano","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115842_bb0800","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202206688","article-title":"Disruption of iron homeostasis to induce ferroptosis with albumin-encapsulated pt(IV) nanodrug for the treatment of non-small cell lung cancer","volume":"19","author":"Tian","year":"2023","journal-title":"Small"},{"key":"10.1016\/j.addr.2026.115842_bb0805","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1021\/acsbiomaterials.0c01095","article-title":"Dual therapeutic targeting of lung infection and carcinoma using lactoferrin-based green nanomedicine","volume":"6","author":"Rofeal","year":"2020","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.addr.2026.115842_bb0810","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12938-019-0624-7","article-title":"Docetaxel-loaded human serum albumin (HSA) nanoparticles: synthesis, characterization, and evaluation","volume":"18","author":"Qu","year":"2019","journal-title":"Biomed. Eng. Online"},{"key":"10.1016\/j.addr.2026.115842_bb0815","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1021\/mp3005935","article-title":"Investigation of the stability and cellular uptake of self-associated monoclonal antibody (MAb) nanoparticles by non-small lung cancer cells","volume":"10","author":"Srinivasan","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115842_bb0820","doi-asserted-by":"crossref","DOI":"10.1002\/pat.6507","article-title":"Review on electrospray nanoparticles for drug delivery: exploring applications","volume":"35","author":"Patel","year":"2024","journal-title":"Polym. Adv. Technol."},{"key":"10.1016\/j.addr.2026.115842_bb0825","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.2147\/DDDT.S169734","article-title":"HA\/HSA co-modified erlotinib-albumin nanoparticles for lung cancer treatment","volume":"12","author":"Shen","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.addr.2026.115842_bb0830","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3390\/pharmaceutics14030543","article-title":"Methods of liposomes preparation: formation and control factors of versatile nanocarriers for biomedical and nanomedicine application","volume":"14","author":"Lombardo","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115842_bb0835","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1539\/joh.48.75","article-title":"Effects of glutaraldehyde exposure on human health","volume":"48","author":"Takigawa","year":"2006","journal-title":"J. Occup. Health"},{"key":"10.1016\/j.addr.2026.115842_bb0840","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11111733","article-title":"Development and mechanistic insight into the enhanced cytotoxic potential of Parvifloron D albumin nanoparticles in EGFR-overexpressing pancreatic cancer cells","volume":"11","author":"Santos-Rebelo","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2026.115842_bb0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115485","article-title":"Albumin nanoparticles and their folate modified counterparts for delivery of a lupine derivative to hepatocellular carcinoma","volume":"167","author":"Wang","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.addr.2026.115842_bb0850","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ijpharm.2017.08.102","article-title":"Erlotinib-loaded albumin nanoparticles: a novel injectable form of erlotinib and its in vivo efficacy against pancreatic adenocarcinoma ASPC-1 and PANC-1 cell lines","volume":"531","author":"Noorani","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115842_bb0855","doi-asserted-by":"crossref","first-page":"31600","DOI":"10.1021\/acsami.7b10408","article-title":"Targeted delivery system based on gemcitabine-loaded silk fibroin nanoparticles for lung Cancer therapy","volume":"9","author":"Mottaghitalab","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.addr.2026.115842_bb0860","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051215","article-title":"Optimization and characterization of protein nanoparticles for the targeted and smart delivery of cytochrome c to non-small cell lung carcinoma","volume":"12","author":"Barcelo-Bovea","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2026.115842_bb0865","article-title":"Controlled delivery of paclitaxel via stable synthetic protein nanoparticles","volume":"7","author":"Mauser","year":"2024","journal-title":"Adv. Ther. (Weinh.)"},{"key":"10.1016\/j.addr.2026.115842_bb0870","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1039\/C8TB03165G","article-title":"The nanoparticle-facilitated autophagy inhibition of cancer stem cells for improved chemotherapeutic effects on glioblastomas","volume":"7","author":"Lu","year":"2019","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.addr.2026.115842_bb0875","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12645-023-00194-7","article-title":"Cabazitaxel-loaded human serum albumin nanoparticles combined with TGF\u03b2-1 siRNA lipid nanoparticles for the treatment of paclitaxel-resistant non-small cell lung cancer","volume":"14","author":"Tan","year":"2023","journal-title":"Cancer Nanotechnol."},{"key":"10.1016\/j.addr.2026.115842_bb0880","doi-asserted-by":"crossref","first-page":"E6595","DOI":"10.1073\/pnas.1705407114","article-title":"Protein nanocages that penetrate airway mucus and tumor tissue","volume":"114","author":"Huang","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.addr.2026.115842_bb0885","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1021\/acsbiomaterials.3c00218","article-title":"Co-encapsulation of hydrophilic and hydrophobic drugs into human H chain ferritin nanocarrier enhances antitumor efficacy","volume":"9","author":"Ning","year":"2023","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.addr.2026.115842_bb0890","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1021\/acsabm.0c01613","article-title":"Tumor-penetrating peptide-functionalized ferritin enhances antitumor activity of paclitaxel","volume":"4","author":"Ma","year":"2021","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.addr.2026.115842_bb0895","doi-asserted-by":"crossref","first-page":"9591","DOI":"10.1039\/C7TB02902K","article-title":"Penetration and drug delivery of albumin nanoparticles into pancreatic multicellular tumor spheroids","volume":"5","author":"Lu","year":"2017","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.addr.2026.115842_bb0900","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1200\/JCO.1999.17.8.2300","article-title":"Randomized study of CODE versus alternating CAV\/EP for extensive-stage small-cell lung Cancer: an intergroup study of the National Cancer Institute of Canada clinical trials group and the southwest oncology group","volume":"17","author":"Murray","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115842_bb0905","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1053\/j.gastro.2004.09.032","article-title":"Chemoembolization for hepatocellular carcinoma","volume":"127","author":"Bruix","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2026.115842_bb0910","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.3390\/cancers15082256","article-title":"A recent review on Cancer nanomedicine","volume":"15","author":"Giri","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2026.115842_bb0915","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121420","article-title":"Bioinspired synthesis of protein\/polysaccharide-decorated folate as a nanocarrier of curcumin to potentiate cancer therapy","volume":"613","author":"Elbialy","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115842_bb0920","doi-asserted-by":"crossref","first-page":"11739","DOI":"10.1039\/C7NR03016A","article-title":"Triptolide and celastrol loaded silk fibroin nanoparticles show synergistic effect against human pancreatic cancer cells","volume":"9","author":"Ding","year":"2017","journal-title":"Nanoscale"},{"key":"10.1016\/j.addr.2026.115842_bb0925","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2026.115842_bb0930","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood-2021-151137","article-title":"A pilot study of CPX-351 (Vyxeos \u00a9) for transplant eligible, higher risk patients with myelodysplastic syndrome","volume":"138","author":"Jacoby","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.addr.2026.115842_bb0935","doi-asserted-by":"crossref","DOI":"10.1038\/s41565-025-01932-1","article-title":"Analysis of multi-drug cancer nanomedicine","author":"Benderski","year":"2025","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2026.115842_bb0940","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.3390\/cancers16132478","article-title":"Emerging therapeutic strategies to overcome drug resistance in Cancer cells","volume":"16","author":"Garg","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2026.115842_bb0945","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jconrel.2023.02.010","article-title":"Targeted nanomedicine: lessons learned and future directions","volume":"355","author":"Veiga","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115842_bb0950","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1021\/mp500394v","article-title":"Doxorubicin-loaded Glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy","volume":"12","author":"Qi","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115842_bb0955","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2021.112162","article-title":"CD44-targeted, indocyanine green-paclitaxel-loaded human serum albumin nanoparticles for potential image-guided drug delivery","volume":"209","author":"Thangavel","year":"2022","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.addr.2026.115842_bb0960","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121248","article-title":"Effect of folate-targeted erlotinib loaded human serum albumin nanoparticles on tumor size and survival rate in a rat model of glioblastoma","volume":"313","author":"Kamali","year":"2023","journal-title":"Life Sci."},{"key":"10.1016\/j.addr.2026.115842_bb0965","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","article-title":"Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review","volume":"65","author":"Maeda","year":"2000","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115842_bb0970","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s44222-024-00154-9","article-title":"The mechanisms of nanoparticle delivery to solid tumours","volume":"2","author":"Nguyen","year":"2024","journal-title":"Nat. Rev. Bioeng."},{"key":"10.1016\/j.addr.2026.115842_bb0975","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24071382","article-title":"Lactosylated albumin nanoparticles: potential drug nanovehicles with selective targeting toward an in vitro model of hepatocellular carcinoma","volume":"24","author":"Teran-Saavedra","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2026.115842_bb0980","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2147\/IJN.S98519","article-title":"Study of the combined treatment of lung cancer using gene-loaded immunomagnetic albumin nanospheres in vitro and in vivo","volume":"11","author":"Zhang","year":"2016","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2026.115842_bb0985","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.125719","article-title":"EGFR targeted albumin nanoparticles of oleanolic acid: in silico screening of nanocarrier, cytotoxicity and pharmacokinetics for lung cancer therapy","volume":"246","author":"Shukla","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.addr.2026.115842_bb0990","article-title":"CD44 promotes cell proliferation in non-small cell lung cancer","author":"Hu","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.addr.2026.115842_bb0995","doi-asserted-by":"crossref","first-page":"414","DOI":"10.18632\/oncotarget.519","article-title":"Folate receptor alpha expression in lung Cancer: diagnostic and prognostic significance","volume":"3","author":"O\u2019Shannessy","year":"2012","journal-title":"Oncotarget"},{"key":"10.1016\/j.addr.2026.115842_bb1000","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1004","article-title":"CD44: from adhesion molecules to signalling regulators","volume":"4","author":"Ponta","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.addr.2026.115842_bb1005","doi-asserted-by":"crossref","first-page":"52553","DOI":"10.18632\/oncotarget.9651","article-title":"Targeting folate receptor alpha for cancer treatment","volume":"7","author":"Cheung","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.addr.2026.115842_bb1010","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.6800","article-title":"RGD peptide in cancer targeting: benefits, challenges, solutions, and possible integrin-RGD interactions","volume":"13","author":"Javid","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.addr.2026.115842_bb1015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s13045-021-01192-1","article-title":"Integrins regulate stemness in solid tumor: an emerging therapeutic target","volume":"14","author":"Xiong","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.addr.2026.115842_bb1020","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009524","article-title":"Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe","volume":"6","author":"Phillips","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2026.115842_bb1025","doi-asserted-by":"crossref","DOI":"10.1039\/D5MH00927H","article-title":"Reimagining drug nanocarriers: clinical realities and smarter strategies for targeted drug delivery","author":"Baker","year":"2025","journal-title":"Mater. Horiz."},{"key":"10.1016\/j.addr.2026.115842_bb1030","doi-asserted-by":"crossref","first-page":"11647","DOI":"10.1039\/D0NR02387F","article-title":"Refined construction of antibody-targeted nanoparticles leads to superior antigen binding and enhanced delivery of an entrapped payload to pancreatic cancer cells","volume":"12","author":"Greene","year":"2020","journal-title":"Nanoscale"},{"key":"10.1016\/j.addr.2026.115842_bb1035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2020.11.010","article-title":"A quantitative view on multivalent nanomedicine targeting","volume":"169","author":"Woythe","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115842_bb1040","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41563-019-0566-2","article-title":"The entry of nanoparticles into solid tumours","volume":"19","author":"Sindhwani","year":"2020","journal-title":"Nat. Mater."},{"key":"10.1016\/j.addr.2026.115842_bb1045","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJM199808133390711","article-title":"Vascular targeting as a strategy for Cancer therapy","volume":"339","author":"Schnitzer","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115842_bb1050","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41568-021-00418-1","article-title":"Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data","volume":"22","author":"Connor","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2026.115842_bb1055","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/s41467-021-22801-0","article-title":"Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer","volume":"12","author":"Wu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115842_bb1060","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222313135","article-title":"The curious case of the HepG2 cell line: 40 years of expertise","volume":"22","author":"Arzumanian","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2026.115842_bb1065","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","article-title":"Pancreatic cancer stroma: an update on therapeutic targeting strategies","volume":"17","author":"Hosein","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.addr.2026.115842_bb1070","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.1038\/s41467-023-41694-9","article-title":"Breaking barriers for glioblastoma with a path to enhanced drug delivery","volume":"14","author":"Noorani","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115842_bb1075","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2015.08.068","article-title":"Preclinical mouse Cancer models: a maze of opportunities and challenges","volume":"163","author":"Day","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.addr.2026.115842_bb1080","doi-asserted-by":"crossref","DOI":"10.1002\/0471141755.ph1435s70","article-title":"Overview of KRAS-driven genetically engineered mouse models of non-small cell lung cancer","volume":"70","author":"Sheridan","year":"2015","journal-title":"Curr. Protoc. Pharmacol."},{"key":"10.1016\/j.addr.2026.115842_bb1085","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/cancers12010014","article-title":"Genetically engineered mouse models for liver cancer","volume":"12","author":"Cho","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2026.115842_bb1090","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/PPO.0b013e31827ab4c4","article-title":"Genetically engineered mouse models of pancreatic Cancer","volume":"18","author":"Westphalen","year":"2012","journal-title":"Cancer J."},{"key":"10.1016\/j.addr.2026.115842_bb1095","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104068","article-title":"Preclinical tumor mouse models for studying esophageal cancer","volume":"189","author":"Mahmoudian","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.addr.2026.115842_bb1100","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3390\/cancers11091335","article-title":"Genetically engineered mouse models of gliomas: technological developments for translational discoveries","volume":"11","author":"Noorani","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2026.115842_bb1105","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jconrel.2014.11.023","article-title":"Detection of hepatocellular carcinoma in transgenic mice by Gd-DTPA- and rhodamine 123-conjugated human serum albumin nanoparticles in T1 magnetic resonance imaging","volume":"199","author":"Watcharin","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115842_bb1110","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.836480","article-title":"3D cell cultures: evolution of an ancient tool for new applications","volume":"13","author":"Cacciamali","year":"2022","journal-title":"Front. Physiol."},{"key":"10.1016\/j.addr.2026.115842_bb1115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s44385-025-00041-x","article-title":"A 3D spheroid model for assessing nanocarrier-based drug delivery to solid tumors","volume":"2","author":"Yadav","year":"2025","journal-title":"NPJ Biomed. Innov."},{"key":"10.1016\/j.addr.2026.115842_bb1120","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s12272-020-01264-9","article-title":"Hyperthermal paclitaxel-bound albumin nanoparticles co-loaded with indocyanine green and hyaluronidase for treating pancreatic cancers","volume":"44","author":"Kim","year":"2021","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.addr.2026.115842_bb1125","doi-asserted-by":"crossref","first-page":"9447","DOI":"10.1021\/acs.jmedchem.2c00698","article-title":"Developing a copper(II) agent based on His-146 and His-242 residues of human serum albumin nanoparticles: integration to overcome cisplatin resistance and inhibit the metastasis of nonsmall cell lung Cancer","volume":"65","author":"Jiang","year":"2022","journal-title":"J. Med. Chem."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26000761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26000761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:26:32Z","timestamp":1777515992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X26000761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":225,"alternative-id":["S0169409X26000761"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2026.115842","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protein-based nanocarriers in the management of hard-to-treat solid tumours","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2026.115842","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115842"}}